April 4, 2014
This article was reported by Red Orbit.
Red Orbit reported on research suggesting that anti-rejection drugs used after transplantation may help fight HIV. The virus remains hidden in the immune system even though patients are adhering to the antiretroviral treatment regimen. The drugs cannot eliminate the hidden virus. Researchers suspect inflammation in the body in response to the infection maintains an environment supportive of the virus. Steven Deeks, MD of the University of California, San Francisco and colleagues investigated whether immunosuppressants could help fight HIV by reducing the inflammation in the body in response to HIV infection.
The researchers analyzed the effect of immunosuppressants on HIV in 91 HIV-positive kidney transplant recipients, who were followed for a median of 3.2 years after transplant. Analysis of participants' blood indicated that the HIV was well-controlled after transplantation and long-term use of an immunosuppressant. Also, patients who took the immunosuppressant sirolimus had fewer HIV-infected blood cells, suggesting that sirolimus may affect the level of HIV persistence.
The researchers concluded that the results highlight the potential role of strong immunosuppressants in finding a cure for HIV.
The full report, "Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients," was published online in the American Journal of Transplantation (2014; doi: 10.1111/ajt.12699).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|